Nektar Therapeutics (NKTR) Shareholder/Analyst Call October 1, 2026 8:00 AM EDT
Company Participants
Vivian Wu
Mary Tagliaferri – Chief Medical Officer
Jonathan Zalevsky – Senior VP and Chief Research & Development Officer
Conference Call Participants
Benjamin Ungar
Julian Harrison – BTIG, LLC, Research Division
Yasmeen Rahimi – Piper Sandler & Co., Research Division
Samantha Semenkow – Citigroup Inc., Research Division
Cha Cha Yang – Jefferies LLC, Research Division
Yu He – H.C. Wainwright & Co, LLC, Research Division
Mayank Mamtani – B. Riley Securities, Inc., Research Division
Jessica Fye – JPMorgan Chase & Co, Research Division
Presentation
Operator
Ladies and gentlemen, thank you for joining us, and welcome to Nektar Therapeutics EADV Analyst and Investor Event. [Operator Instructions] I will now hand the conference over to Vivian Wu, Investor Relations and Corporate Affairs. Vivian, please go ahead.
Vivian Wu
Thank you, and good morning, everyone. Thank you for joining us today to discuss new data being presented at the EADV 2026 Congress. On today’s call, we expect to make forward-looking statements regarding our business, including statements regarding the potential of and future development plans for Rezpegaldesleukin, the timing and plan for future clinical data presentations and other statements regarding the future of our business. Because forward-looking statements relate to the future, they are subject to uncertainties and risks that are difficult to predict, many of which are outside of our control.
Our actual results may differ materially from these statements. Important risks and uncertainties are set forth in our most recent annual report and quarterly report on Form 10-Q available at SEC.gov. We undertake no obligation to update any of these forward-looking statements, whether as a result of new information, future developments or otherwise. A webcast of this call will be available on the IR page of Nektar’s website at nektar.com. Today, you will hear from Dr. Jonathan Zalevsky, our Chief Research and Development Officer; and
